| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H16ClN5O2 |
| Molecular Weight | 381.816 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](OC1=NN=C(N1C)C2=CC=NC=C2)C3=NOC(=C3)C4=CC(Cl)=CC=C4
InChI
InChIKey=SXWHYTICXCLKDG-GFCCVEGCSA-N
InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1
| Molecular Formula | C19H16ClN5O2 |
| Molecular Weight | 381.816 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
AstraZeneca was developing AZD-2066, a metabotropic glutamate receptor 5 (mGLUR5) antagonist, for the oral treatment of pain indications (e.g. chronic neuropathic pain and painful diabetic neuropathies), depressive disorders and gastro-oesophageal reflux disease. AZD-2066 had been in phase II clinical trials by AstraZeneca for the treatment of diabetic neuropathic pain and phase I for the treatment of gastrooesophageal reflux disease (GERD). However, this reasearch had being discontinued.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Treatment of pain: capsule, once daily, 12 mg AZD-2066 day 1-4 and 18 mg AZD2066 day 5-28.
Route of Administration:
Oral
In vitro inhibition by AZD-2066 was observed for the following CYP:
CYP1A2 (IC50=14.3 uM), CYP2B6 (IC50=7.4 uM), CYP2C9 (IC50=4.9 μM), CYP2C19 (IC50=9.6 μM) and
CYP2D6 (IC50=15 μM). Inhibition of CYP3A4 was also
observed, with 60 and 80 % of inhibition at the highest tested
concentration of AZD-2066 (300 uM) with midazolam and
testosterone as the probe substrates, respectively.
